Related Experiment Video

Updated: Oct 21, 2025

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.9K

Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials

Bilal Asif1, Christopher Koh2

  • 1Digestive Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, USA.

Expert Opinion on Investigational Drugs
|September 6, 2021
PubMed
Abstract

Insights

Chronic Hepatitis D virus (HDV) infection causes severe liver disease. New therapies targeting the HDV lifecycle are in development, offering hope for viral eradication.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Chronic Hepatitis D virus (HDV) infection is a significant global health concern.
  • HDV infection leads to rapid liver disease progression, increased mortality, and hepatocellular carcinoma.
  • Current therapies for HDV are largely ineffective.

Purpose of the Study:

  • To review the clinical impact of HDV infection.
  • To provide an in-depth analysis of the HDV lifecycle.
  • To examine current and novel drug targets and investigational therapies for HDV.

Main Methods:

  • Literature review focusing on the HDV lifecycle and therapeutic targets.
  • Searches conducted on PubMed and clinicaltrials.gov databases.
  • Emphasis on the most up-to-date investigational therapies for chronic HDV infection.

Main Results:

  • Understanding the HDV lifecycle has identified new potential drug targets.
  • A growing number of investigational therapeutics are under exploration for HDV.
  • These novel therapies hold the potential for successful viral eradication.

Conclusions:

  • Despite limited current treatment options, advancements in understanding HDV biology are promising.
  • Investigational therapies targeting the HDV lifecycle represent a new frontier in managing chronic HDV infection.
  • Future research and clinical trials are crucial for achieving viral eradication.
Keywords:
BulevirtideHepatitis Dclinical trialsimmunomodulationinvestigational drugs

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.4K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.9K

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.9K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
46